8-K: Sana Biotechnology Announces Positive Clinical Data and First Quarter 2025 Financial Results

Sana Biotechnology reports positive clinical results from a type 1 diabetes study and provides business updates for the first quarter of 2025, while also announcing a new sales agreement for up to $119 million in common stock.

Summary

• Sana Biotechnology reported its first quarter 2025 financial results and business updates on May 8, 2025.
• The company presented positive 4and 12-week clinical results from an ongoing type 1 diabetes study.
• The study showed that hypoimmune-modified pancreatic islet cells transplanted without immunosuppression overcome immune recognition, while continuing to function and persist with stable C-peptide production post-transplant.
• Sana is enrolling patients in the GLEAM trial for SC291 in B-cell mediated autoimmune diseases and the VIVID trial for SC262 in relapsed/refractory B-cell malignancies, with clinical data expected in 2025.
• Preclinical data in non-human primates showed safety and deep B-cell depletion using a surrogate for SG299, an in vivo CAR T with CD8-targeted fusogen delivery of a CD19-directed CAR.
• The company expects to file investigational new drug applications (INDs) for SC451 in type 1 diabetes and for SG299 in B-cell related diseases as early as 2026.
• Sana's Q1 2025 cash position was $104.7 million, with an expected cash runway into 2026.
• The company has entered into a sales agreement with TD Securities (USA) LLC to sell shares of its common stock with an aggregate offering price of up to $119.0 million through an at-the-market offering program.
• Sana terminated its prior sales agreement with TD Cowen, under which it had sold approximately 4.9 million shares for gross proceeds of approximately $30.6 million, leaving an unsold aggregate offering price of approximately $119.4 million.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook, highlighting promising clinical data and pipeline advancements. However, the company's cash burn and need for potential future funding temper the overall sentiment.

Positives

• Positive clinical data from the UP421 type 1 diabetes study indicates potential for immune evasion and sustained islet cell function without immunosuppression.
• Advancement of the pipeline with ongoing clinical trials (GLEAM and VIVID) and expected data readouts in 2025.
• Promising preclinical data for SG299 suggests potential for in vivo CAR T therapy with deep B-cell depletion.
• Expected IND filings for SC451 and SG299 as early as 2026 represent significant milestones.
• A cash position of $104.7 million provides a runway into 2026.

Negatives

• The company's cash decreased by $47.8 million in Q1 2025, primarily due to cash used in operations of $48.7 million.
• Research and development expenses decreased by $19.3 million, primarily due to lower personnel-related, laboratory, and research costs due to a decrease in headcount and the portfolio prioritization announced in the fourth quarter of 2024, a decrease in clinical development costs primarily related to the suspension of the ARDENT trial in the fourth quarter of 2024 and clinical development milestones recorded in the first quarter of 2024 that did not recur in 2025, and a decrease in facility and other allocated costs primarily due to the portfolio prioritization announced in the fourth quarter of 2024.
• General and administrative expenses decreased by $4.8 million, primarily due to lower personnel-related costs, including non-cash stock-based compensation, due to a decrease in headcount, and decreased legal and consulting fees.

Risks

• The company's cash runway is only projected into 2026, indicating a potential need for additional funding in the future.
• The success of clinical trials and IND filings is subject to inherent risks and uncertainties in drug development.
• The market value of the company's stock can significantly impact the value of success payment liabilities and contingent consideration.
• The company has terminated a previous sales agreement and entered into a new one, which may indicate a change in financial strategy or market conditions.

Future Outlook

Sana expects to report clinical data from the GLEAM and VIVID trials in 2025 and file INDs for SC451 and SG299 as early as 2026, with a cash runway into 2026.

Management Comments

• Steve Harr, Sana's President and Chief Executive Officer, stated that the company has made significant progress in 2025 toward a functional cure for type 1 diabetes.
• He highlighted the 12-week clinical data for UP421, showing that hypoimmune-modified pancreatic islets continue to evade immune detection and function three months after transplant.
• He also mentioned the establishment of a genomically stable, gene-modified master cell bank, which clears the path toward an IND as early as 2026 and makes a scalable solution for people with T1D a realistic possibility.

Industry Context

Sana Biotechnology's focus on engineered cells as medicines aligns with the broader industry trend of developing innovative therapies for diseases with unmet needs, particularly in areas like type 1 diabetes, autoimmune diseases, and oncology. The company's hypoimmune platform and in vivo CAR T technology represent novel approaches to cell therapy, potentially offering advantages over traditional methods.

Comparison to Industry Standards

• Sana's approach to type 1 diabetes, using hypoimmune-modified islet cells, is comparable to efforts by companies like Vertex Pharmaceuticals (ViaCyte acquisition) which is developing stem cell-derived islet replacement therapies.
• The clinical data presented for UP421, showing immune evasion without immunosuppression, is a significant advancement, as many cell therapies require immunosuppressants, which can have adverse side effects.
• Sana's allogeneic CAR T cell programs (SC291 and SC262) compete with other companies developing allogeneic CAR T therapies, such as Allogene Therapeutics and CRISPR Therapeutics, aiming to provide off-the-shelf CAR T options.
• The in vivo CAR T approach (SG299) is a novel strategy that differentiates Sana from companies focusing on ex vivo CAR T cell manufacturing, potentially offering advantages in terms of scalability and cost.

Stakeholder Impact

• Shareholders: The positive clinical data and pipeline advancements could positively impact shareholder value, while the potential capital raise could dilute existing shares.
• Employees: The company's progress and financial stability support job security and potential growth opportunities.
• Patients: The development of novel therapies for type 1 diabetes, autoimmune diseases, and cancer could provide new treatment options and improve patient outcomes.
• Partners: The company's collaborations and partnerships are essential for advancing its pipeline and technology platforms.

Next Steps

• Continue enrolling patients in the GLEAM and VIVID trials.
• Report clinical data from the GLEAM and VIVID trials in 2025.
• Share additional data from the UP421 study at scientific conferences and/or in peer-reviewed publications.
• File INDs for SC451 and SG299 as early as 2026.
• Execute the at-the-market offering program with TD Securities (USA) LLC.

Key Dates

Keywords

Sana Biotechnology, engineered cells, type 1 diabetes, CAR T therapy, clinical trials, financial results, SC291, SC262, SG299, UP421, IND filing, cash runway, TD Cowen, TD Securities, at-the-market offering